novel
chemoprophylact
therapeut
vector
control
intervent
could
support
acceler
malaria
elimin
effort
ivermectin
mass
drug
administr
mda
propos
malaria
control
tool
sinc
make
blood
treat
person
lethal
anophel
mosquito
vector
malaria
repeat
ivermectin
mda
burkina
faso
abl
reduc
malaria
transmiss
human
ivermectin
safe
toler
endectocid
drug
use
wide
veterinari
human
medicin
combat
intern
extern
parasit
ivermectin
shown
inhibit
liverstag
develop
plasmodium
berghei
vitro
human
hepatoma
cell
line
model
vivo
mous
model
vitro
half
maxim
inhibitori
concentr
ic
ivermectin
p
berghei
inhibit
ic
higher
blood
level
achiev
treat
human
howev
mice
oral
dose
ivermectin
mgkg
hour
hour
sporozoit
challeng
demonstr
liverstag
inhibit
equal
primaquin
mgkg
dose
schedul
human
equival
dose
hed
evalu
mice
would
correl
ivermectin
dose
rang
mgkg
thu
ivermectin
promis
human
malaria
chemoprophylaxi
ivermectin
dose
high
mgkg
safe
administ
human
ivermectin
prevent
plasmodium
liverstag
infect
ivermectin
chemoprophylaxi
could
consid
high
model
evalu
causal
prophylaxi
ie
protect
develop
liver
schizont
hypnozoiticid
ie
radic
cure
liver
hypnozoit
efficaci
compound
ivermectin
use
rhesu
macaqu
coloni
treat
mite
lice
intestin
helminth
ascari
trichuri
strongyloid
fulleborni
studi
demonstr
oral
ivermectin
safe
macaqu
dose
mgkg
day
macaqu
ideal
anim
model
ivermectin
human
treatment
howev
studi
date
evalu
pharmacokinet
repeat
ivermectin
treatment
rhesu
macaqu
combin
chloroquin
evalu
vitro
vivo
liverstag
effect
ivermectin
p
cynomolgi
rhesu
macaqu
liver
hepatocyt
infect
macaqu
safeti
pharmacokinet
repeat
oral
ivermectin
dose
without
chloroquin
macaqu
also
present
result
ivermectin
efficaci
liverstag
parasit
initi
evalu
use
vitro
p
cynomolgi
liver
model
util
primari
rhesu
macaqu
hepatocyt
order
close
resembl
vivo
antirelaps
mode
drug
regimen
defin
treatment
mode
either
prophylact
mode
ie
drug
administ
sporozoit
day
thereaft
radic
cure
mode
ie
drug
administ
day
post
sporozoit
infect
similar
previous
describ
method
prophylact
mode
ivermectin
show
margin
vitro
causal
protect
develop
p
cynomolgiinfect
rhesu
macaqu
hepatocyt
liver
schizont
ic
hypnozoit
ic
figur
howev
radic
cure
mode
ivermectin
activ
develop
p
cynomolgi
liver
schizont
establish
hypnozoit
even
dose
high
initi
concentr
inhibit
liver
schizont
ic
hypnozoit
ic
ls
stage
graph
bar
repres
mean
standard
deviat
biolog
replic
n
experiment
replic
n
one
advers
event
singl
macaqu
vomit
three
hour
first
oral
dose
ivermectin
mgkg
administ
monotherapi
one
day
prior
p
cynomolgi
sporozoit
inject
advers
event
occur
ivermectin
mgkg
coadminist
chloroquin
abnorm
hematolog
outcom
observ
ivermectin
alon
ivermectin
plu
chloroquin
coadministr
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
primari
bloodstag
parasitemia
greater
detect
ten
day
post
inocul
neg
posit
control
group
macaqu
ivermectin
high
mgkg
low
mgkg
dose
group
remain
macaqu
group
reach
greater
eleven
day
post
inocul
day
last
ivermectin
administr
primari
infect
bloodstag
parasitemia
clear
neg
control
group
ten
day
chloroquin
mgkg
bloodand
liverstag
parasit
posit
control
group
seven
day
chloroquin
mgkg
primaquin
mgkg
bloodstag
parasitemia
clear
three
macaqu
lowdos
ivermectin
group
seven
day
ivermectin
mgkg
ten
day
chloroquin
mgkg
two
three
macaqu
clear
primari
infect
bloodstag
parasitemia
dose
group
ivermectin
mgkg
seven
day
chloroquin
mgkg
ten
day
one
macaqu
clear
ivermectin
mgkg
chloroquin
mgkg
seven
day
howev
first
relaps
occur
within
week
approxim
time
neg
control
ivermectin
group
signific
differ
time
stage
parasitemia
treatment
logrank
mantel
cox
test
p
first
relaps
infect
bloodstag
parasitemia
clear
neg
control
chloroquin
mgkg
alon
seven
day
first
relaps
infect
bloodstag
parasitemia
clear
high
mgkg
low
mgkg
dose
ivermectin
group
given
combin
chloroquin
mgkg
seven
day
approxim
week
later
second
relaps
occur
neg
control
ivermectin
highand
lowdos
treat
macaqu
signific
differ
time
bloodstag
parasitemia
treatment
logrank
mantel
cox
test
p
point
second
relaps
ivermectingroup
macaqu
treat
primaquin
mgkg
chloroquin
mgkg
seven
day
posit
control
group
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
treat
primaquin
mgkg
chloroquin
mgkg
seven
day
point
primari
infect
relaps
remaind
studi
figur
neg
control
group
treat
primaquin
mgkg
chloroquin
mgkg
seven
day
point
third
relaps
data
shown
tabl
illustr
pharmacokinet
paramet
ivermectin
administ
alon
first
seventh
last
dose
auc
extrap
percentag
areaunderthecurv
infin
due
extrapol
last
collect
time
point
infin
auc
exposur
hour
auc
inf
total
exposur
clf
appar
clearanc
vzf
appar
volum
distribut
c
max
maximum
concentr
c
max
dose
maximum
concentr
divid
dose
administ
elimin
halflif
max
time
reach
maximum
concentr
tabl
pharmacokinet
paramet
ivermectin
coadminist
chloroquin
st
th
dose
describ
noncompartment
analysi
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
tabl
illustr
pharmacokinet
paramet
ivermectin
administ
chloroquin
mgkg
first
seventh
last
dose
auc
extrap
percentag
areaunderthecurv
infin
due
extrapol
last
collect
time
point
infin
auc
exposur
hour
auc
inf
total
exposur
clf
appar
clearanc
vzf
appar
volum
distribut
c
max
maximum
concentr
c
max
dose
maximum
concentr
divid
dose
administ
elimin
halflif
max
time
reach
maximum
concentr
cq
chloroquin
delay
patenc
first
bloodstag
p
cynomolgi
infect
either
lowor
highdos
ivermectin
group
figur
ivermectin
display
level
liver
schizont
efficaci
vitro
howev
lack
delay
bloodstag
patenc
suggest
minim
impact
ivermectin
liver
schizont
develop
admittedli
inject
one
million
p
cynomolgi
sporozoit
macaqu
set
high
bar
drug
requir
one
sporozoit
develop
liver
schizont
continu
bloodstag
malaria
infect
contrast
singl
mosquito
predict
deliv
sporozoit
blood
feed
best
knowledg
highest
repeat
dose
ivermectin
pharmacokinet
investig
mammal
speci
signific
chang
clf
note
studi
small
sampl
size
three
macaqu
per
treat
group
thu
ivermectin
autoinhibit
warrant
evalu
futur
trial
human
three
repeat
dose
ivermectin
mg
everi
third
day
inhibit
c
max
compar
first
third
dose
suggest
lack
autoinhibit
fvb
mice
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
administ
oral
ivermectin
mgkg
twice
week
five
week
reduct
hour
postdos
plasma
ivermectin
concentr
increas
major
metabolit
concentr
suggest
induct
metabol
macaqu
coadministr
ivermectin
mgkg
chloroquin
mgkg
seven
day
safe
welltoler
coadministr
chloroquin
ivermectin
effect
c
max
auc
ivermectin
chloroquin
tabl
figur
mgkg
dose
macaqu
approxim
hed
mgkg
total
mgkg
mgkg
total
mgkg
respect
suggest
repeat
daili
dose
ivermectin
mgkg
could
use
combin
chloroquin
human
billion
ivermectin
chloroquin
treatment
administ
human
limit
safeti
evid
coadministr
one
studi
plasmodium
vivax
coadminist
ivermectin
mgkg
singledos
chloroquin
mgkg
first
day
mgkg
second
third
day
ten
person
advers
event
passiv
report
ivermectin
chloroquin
hydroxychloroquin
shown
vitro
inhibit
replic
novel
sever
acut
respiratori
syndrom
coronaviru
three
drug
distribut
lung
tissu
higher
concentr
plasma
chloroquin
hydroxychloroquin
rat
hydroxychloroquin
mice
ivermectin
goat
cattl
preliminari
clinic
evid
observ
registrybas
studi
found
patient
ventil
receiv
dose
ivermectin
significantli
lower
mortal
rate
durat
hospit
durat
intens
care
unit
preclin
safeti
evid
macaqu
present
vitro
efficaci
preliminari
clinic
report
ivermectin
efficaci
patient
warrant
investig
ivermectin
chloroquin
hydroxychloroquin
infect
person
copyright
holder
preprint
version
post
april
http
dmso
use
final
concentr
serial
dilut
ivermectin
administ
two
treatment
mode
prophylact
radic
cure
prophylact
mode
drug
present
day
start
point
sporozoit
addit
altern
radic
cure
mode
drug
present
day
start
day
post
sporozoit
inocul
imag
data
analysi
drug
plate
complet
use
operetta
cl
imag
system
harmoni
softwar
perkin
elmer
waltham
usa
imag
acquir
use
tritc
dapi
bright
field
channel
magnif
parasit
count
tritc
channel
identifi
area
mean
intens
maximum
intens
cell
round
ivermectin
ic
curv
percent
inhibit
gener
use
parasit
popul
count
control
calcul
averag
replic
report
ic
obtain
two
experiment
replic
three
biolog
replic
prophylact
mode
two
biolog
replic
radic
cure
mode
use
anophel
diru
mosquito
use
produc
p
cynomolgi
b
strain
sporozoit
donor
macaqu
infect
bloodstag
p
cynomolgi
parasit
liverstag
challeng
macaqu
inject
intraven
x
p
cynomolgi
sporozoit
inoculum
pb
bovin
serum
albumin
usamdafrim
colonyborn
rhesu
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
macaqu
indian
origin
use
studi
ten
healthi
macaqu
five
male
five
femal
year
old
rang
weight
kg
select
studi
macaqu
neg
simian
retrovirus
simian
herp
b
viru
two
macaqu
serv
neg
control
treat
initi
seven
day
vehicl
control
treat
seven
day
chloroquin
mgkg
parasitemia
reach
parasit
per
primari
infect
first
relaps
seven
day
chloroquin
mgkg
plu
primaquin
mgkg
second
relaps
two
macaqu
serv
posit
causal
prophylaxi
control
treat
initi
seven
day
vehicl
control
treat
seven
day
chloroquin
mgkg
plu
primaquin
mgkg
point
primari
infect
parasit
reach
parasit
per
studi
drug
administ
restrain
consciou
macaqu
via
nasogastr
intub
mlkg
bodi
weight
sparmectin
sparhawk
laboratori
inc
lenexa
ks
usa
watersolubl
formul
ivermectin
develop
oral
use
hors
ivermectin
dilut
steril
water
administ
via
nasogastr
rout
six
macaqu
receiv
ivermectin
three
dose
mgkg
three
highdos
mgkg
seven
consecut
day
start
one
day
sporozoit
challeng
primari
bloodstag
infect
occur
bloodstag
parasitemia
reach
parasit
per
macaqu
receiv
seven
day
chloroquin
mgkg
plu
ivermectin
mgkg
highdos
group
seven
day
chloroquin
mgkg
plu
ivermectin
mgkg
lowdos
group
relaps
occur
bloodstag
parasitemia
reach
parasit
per
macaqu
receiv
seven
day
chloroquin
plu
ivermectin
mgkg
lowand
highdos
group
second
relaps
occur
macaqu
treat
seven
day
chloroquin
mgkg
primaquin
mgkg
termin
experi
neg
posit
control
group
macaqu
treat
seven
day
chloroquin
mgkg
primaquin
mgkg
third
relaps
first
infect
respect
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
macaqu
observ
sever
time
first
hour
post
dose
least
three
time
day
remaind
studi
clinic
sign
neurolog
eg
ataxia
lethargi
imbal
gastroenterolog
eg
diarrhea
vomit
weight
loss
complic
venou
blood
collect
select
time
point
macaqu
becom
blood
smear
posit
hematocrit
white
red
blood
cell
count
determin
thick
thin
blood
smear
sampl
made
examin
daili
quantifi
malaria
parasitemia
sampl
fix
methanol
stain
giemsa
stain
blood
smear
examin
presenc
absenc
bloodstag
parasit
oilimmers
object
parasit
found
microscop
oilimmers
thick
field
approxim
white
blood
cell
wbc
smear
consid
neg
parasitemia
level
report
number
parasit
per
mm
whole
blood
parasit
count
per
number
wbc
red
blood
cell
rbc
ie
per
wbc
rbc
parasitemia
level
calcul
appropri
total
blood
cell
count
white
red
per
mm
blood
sampl
ml
collect
day
sporozoit
inject
sampl
schedul
occur
control
macaqu
addit
sampl
day
obtain
infect
blood
control
use
method
develop
blood
collect
store
edta
tube
kept
frozen
parasit
dna
extract
ul
edta
whole
blood
use
dna
blood
kit
autom
advanc
xl
purif
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
system
qiagen
hilden
germani
real
time
pcr
p
cynomolgi
detect
perform
use
rotor
gene
q
hrm
platform
qiagen
hilden
germani
primer
probe
design
target
p
cynomolgi
small
subunit
rrna
bloodstag
parasit
genbank
access
number
primer
probe
sequenc
follow
p
cynomolgi
fwd
blood
sampl
pharmacokinet
time
point
prior
first
ivermectin
dose
first
dose
hour
consecut
day
dose
th
dose
hour
day
primari
infect
occur
blood
sampl
schedul
repeat
blood
pharmacokinet
collect
first
second
relaps
blood
collect
heparin
sodium
vacutain
tube
centrifug
rpm
min
supernat
plasma
transfer
kept
analysi
perform
plasma
separ
two
tube
tube
ivermectin
extract
use
protein
precipit
method
acn
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
water
acquiti
uplc
beh
column
mm
particl
size
precolumn
materi
use
separ
compound
gradient
mobil
phase
use
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
